The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGraft Polymer Regulatory News (GPL)

Share Price Information for Graft Polymer (GPL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.12
Ask: 0.13
Change: 0.00 (0.00%)
Spread: 0.01 (8.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.125
GPL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on recent developments

9 May 2024 07:00

RNS Number : 6920N
Graft Polymer (UK) PLC
09 May 2024
 

9 May 2024

 

Graft Polymer (UK) Plc

(the "Company")

 

Update on recent developments

 

Graft Polymer (UK) Plc (LSE:GPL) is pleased to provide an overview on recent progress as it focuses on opportunities in the healthcare industry through its Graft Bio division.

 

Publication of accounts

On 30 April 2024, the Company announced the publication of its audited accounts for the year ended 31 December 2023 (the "2023 Accounts"). The 2023 Accounts revealed that the challenges faced by the Company in 2022 had continued into 2023. It had become necessary to reflect this performance, in the 2023 Accounts, as a full impairment of the Company's investment in its Slovenian industrial plastics manufacturing facility (Graft Polymer d.o.o). This impairment was necessary due to slow revenue uptake and ongoing constraints, with a forecasted negative cash position in the near future.

 

Disposal of Graft Polymer d.o.o

On 3 May 2024, and as anticipated in the announcement of the 2023 Accounts, the Company announced the disposal of Graft Polymer d.o.o. to a private consortium in Slovenia for nominal consideration.

 

Board changes

On 15 March 2024, the Company appointed Nicholas Nelson as Chairman following his co-investment in the Company, via a loan facility, to cover the Company's short term expenditure in preparation of a planned equity fundraise.

On 2 May 2024, healthcare industry executive Anthony Tennyson was appointed as Chief Executive Officer of the Company to oversee a comprehensive review of the Company's operations.

 

Operational review and focus on the future

The operational review referenced in the Company's announcement of 2 May 2024 has begun. The review is focused on the Company's healthcare industry orientated Graft Bio division which, in the Directors' opinion, has strong prospects through its intellectual property, licensing agreements, and sales contracts. Shareholders will be kept informed as details of the review emerge.

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director: anthonytennyson@graftpolymer.com

Yifat Steuer, CFO and Executive Director

Allenby Capital (Broker) Phone: +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance)

Guy McDougall (Sales)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUPUQUAUPCGMR
12
Date   Source Headline
9th May 20247:00 amRNSUpdate on recent developments
7th May 20247:00 amRNSGrant of Haemostatic Hydrogel Patent
3rd May 20247:00 amRNSDivestment of Graft Polymer d.o.o – Slo facility
2nd May 20247:00 amRNSReplacement of Chief Executive Officer
30th Apr 20245:05 pmRNSAnnual Financial Report
23rd Apr 20244:17 pmRNSLoan facility update
15th Mar 20247:00 amRNSChairman & Directorate Change & Financial Update
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSGM Statement
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSHolding(s) in Company
8th Jan 20245:00 pmRNSDirector/PDMR Shareholding
27th Dec 20237:00 amRNSGM Notice 8th January 2024
22nd Dec 20237:00 amRNSPlacing of New Ordinary Shares
9th Oct 20237:00 amRNSPivotal Agreement within European Consortium
27th Sep 20237:02 amRNSUpdated Investor Presentation
27th Sep 20237:00 amRNSInterim Financial Results
11th Sep 20237:00 amRNSR&D Agreement with Slovenian Faculty
4th Sep 20237:00 amRNSR&D and supply agreement with FORPET BALTIC
30th Aug 20237:00 amRNSR&D Supply Agreement Signed
23rd Aug 20237:00 amRNSGraft Bio signs manufacturing services agreement
27th Jul 202311:54 amRNSResult of AGM
26th Jul 20237:00 amRNSDistribution agreement with US Inter-Technologies
6th Jul 20237:00 amRNSNew R&D and Supply Agreement with Gabriel Chemie
5th Jul 20237:00 amRNSOperational Update
4th Jul 20237:00 amRNSAGM Notice
16th May 20232:08 pmRNSDirector Share Purchase
27th Apr 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSGraftBio - MGC Pharma Update
20th Mar 20237:00 amRNSCorporate Presentation
9th Feb 20237:00 amRNSUpdate: New Product Lines & Facility Expansion
30th Sep 20227:00 amRNSInterim Results
20th Sep 20227:00 amRNSNew Corporate Presentation
18th Aug 202210:00 amRNSFirst Commercial Purchase Order for GraftBio
28th Jul 202212:30 pmRNSResult of AGM
4th Jul 20224:50 pmRNSNotice of AGM
29th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSOperational Update
17th Jun 20227:00 amRNSGraftBio IP – MGC Pharma Update
18th May 20227:00 amRNSDirector Share Purchase
12th May 20227:00 amRNSHACCP Certificate Enabling Access to B2C Market
22nd Apr 20227:17 amRNSGrant of patents
7th Apr 20227:00 amRNSPre-payment for equipment
6th Apr 202211:50 amRNSDirector/PDMR Shareholding
21st Feb 20227:00 amRNSUpdate on Operations
15th Feb 20227:00 amRNSChange of Year End
25th Jan 20227:00 amRNSBusiness Update
11th Jan 20227:00 amRNSInvestor Presentation
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.